On March 1, 2017, GRAIL, Inc. announced that it raised over $900 million through the first close of its previously announced Series B financing. In connection with the first Series B closing, GRAIL repurchased a portion of Illumina’s stake, following which Illumina now owns slightly less than 20 percent and no longer has representation on GRAIL’s board of directors. Going forward, Illumina will reflect its remaining ownership of GRAIL as a cost-method investment in Illumina’s financial statements.

About Illumina, Inc. (NASDAQ:ILMN)

Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.

Illumina, Inc. (NASDAQ:ILMN) Recent Trading Information

Illumina, Inc. (NASDAQ:ILMN) closed its last trading session 00.00 at 167.40 with 1,534,157 shares trading hands.